DRUG 株価推移チャート
DRUG 財務
Bright Minds Biosciences Inc.
$82.78
11.05%
$8.23
終値： May 20, 16:00:00 GMT-4
$82.78
0%
$0
アフターマーケット：May 20, 20:00:00 GMT-4
戻る
Bright Minds Biosciences Inc. (DRUG) 財務
収入
貸借対照表
現金の流れ
年次
四半期
DRUG 収入
金額は百万米ドル単位。会計年度は2月から1月まで。
Follow-Up Questions
Bright Minds Biosciences Inc.の主要な財務諸表は何ですか？
DRUGの主要な財務比率は何ですか？
Bright Minds Biosciences Inc.の収益はセグメントまたは地域別にどのように分けられていますか？
Bright Minds Biosciences Inc.は収益を上げていますか？
Bright Minds Biosciences Inc.に負債はありますか？
Bright Minds Biosciences Inc.の発行済株式数は何株ですか？
主要データ
前終値
$74.54
始値
$76.99
当日レンジ
$76.99 - $83.17
52週レンジ
$23.17 - $123.75
取引高
200.5K
平均取引高
168.4K
配当利回り
--
1株当たり利益(TTM)
-2.01
時価総額
$810.1M
Bright Minds Biosciences Inc.とは何ですか？
Bright Minds Biosciences, Inc. is a biotechnology company, which engages in the development of therapeutics. The company is headquartered in New York City, New York. The company went IPO on 2021-02-08. The firm is focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, depression, and other central nervous system (CNS) disorders. Its Serotonin (5-HT) is a neurotransmitter in the brain and modulates many biological functions. Dysfunction of serotonin receptors, transporters, and associated neurocircuits is fundamental to many diseases including epilepsies and neuro psychiatric. Its pipeline includes BMB-101, BMB-xxx, BMB-201, and BMB-202. The firm has a portfolio of patented, selective serotonin (5-HT2C, 5-HT2A and 5-HT2C/A-receptor subtypes) agonists that were identified by using high-throughput screening methods in combination with advanced molecular modeling techniques to interrogate the interaction between the drug and its targeted receptors to increase downstream signaling.
